Foley J. Mark's Insider Trades & SAST Disclosures
Foley J. Mark's most recent trade in Glaukos Corporation was a trade of 25,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 26, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Foley J. Mark.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Glaukos Corporation | Mark J. Foley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corporation | Mark J. Foley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.00 per share. | 26 Feb 2025 | 25,000 | 59,936 (0%) | 0% | 32 | 800,000 | Common Stock |
| Glaukos Corporation | Mark J. Foley | Director | Sale of securities on an exchange or to another person at price $ 120.72 per share. | 26 Feb 2025 | 20,687 | 54,249 (0%) | 0% | 120.7 | 2,497,335 | Common Stock |
| Glaukos Corporation | Mark J. Foley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 26 Feb 2025 | 15,000 | 74,936 (0%) | 0% | 24.7 | 370,350 | Common Stock |
| Glaukos Corporation | Mark J. Foley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 27,933 | 1,024,868 (1%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 2.18 per share. | 31 Dec 2024 | 1,000 | 996,935 (1%) | 0% | 2.2 | 2,185 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 2.18 per share. | 30 Jun 2024 | 1,000 | 995,935 (1%) | 0% | 2.2 | 2,185 | Common Stock |
| Glaukos Corporation | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 1,716 | 34,936 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 1,246 | 1,246 | - | - | Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.31 per share. | 15 Mar 2024 | 17,228 | 994,935 (1%) | 0% | 5.3 | 91,395 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.30 per share. | 15 Mar 2024 | 3,305 | 1,012,163 (1%) | 0% | 5.3 | 17,533 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Purchase of securities on an exchange or from another person at price $ 6.98 per share. | 06 Mar 2024 | 30,000 | 1,015,468 (1%) | 0% | 7.0 | 209,400 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 70,750 | 985,468 (1%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | J. Mark Foley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.28 per share. | 23 Feb 2024 | 10,000 | 37,780 (0%) | 0% | 7.3 | 72,750 | Common Stock |
| Glaukos Corporation | J. Foley Mark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corporation | Foley Mark J. | Director | Sale of securities on an exchange or to another person at price $ 92.87 per share. | 23 Feb 2024 | 4,560 | 33,220 (0%) | 0% | 92.9 | 423,487 | Common Stock |
| Revance Therapeutics Inc | J. Mark Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 1,070,001 | 1,070,001 | - | - | Performance Stock Units | |
| Revance Therapeutics Inc | Foley J. Mark | Director, CEO | Grant, award, or other acquisition of securities at price $ 7.47 per share. | 31 Dec 2023 | 264 | 914,718 (1%) | 0% | 7.5 | 1,972 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 122,143 | 962,518 (1%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.91 per share. | 11 Aug 2023 | 48,064 | 914,454 (1%) | 0% | 18.9 | 908,890 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Sale of securities on an exchange or to another person at price $ 22.57 per share. | 03 Aug 2023 | 26,279 | 840,375 (1%) | 0% | 22.6 | 593,151 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Sale of securities on an exchange or to another person at price $ 24.94 per share. | 30 Jun 2023 | 26,279 | 866,654 (1%) | 0% | 24.9 | 655,333 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 15.61 per share. | 30 Jun 2023 | 1,000 | 892,933 (1%) | 0% | 15.6 | 15,606 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Sale of securities on an exchange or to another person at price $ 30.72 per share. | 09 Jun 2023 | 31,279 | 891,933 (1%) | 0% | 30.7 | 960,928 | Common Stock |
| Glaukos Corporation | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 3,230 | 27,780 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.65 per share. | 15 Mar 2023 | 5,341 | 818,010 (1%) | 0% | 30.7 | 163,702 | Common Stock |
| Glaukos Corporation | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 2,948 | 24,550 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 12.18 per share. | 31 Dec 2022 | 605 | 718,092 (1%) | 0% | 12.2 | 7,369 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.97 per share. | 13 Oct 2022 | 49,274 | 717,487 (1%) | 0% | 27.0 | 1,328,920 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2022 | 175,649 | 893,741 (1%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Sale of securities on an exchange or to another person at price $ 31.59 per share. | 22 Sep 2022 | 70,390 | 823,351 (1%) | 0% | 31.6 | 2,223,360 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 11.75 per share. | 30 Jun 2022 | 1,000 | 766,761 (1%) | 0% | 11.7 | 11,747 | Common Stock |
| Glaukos Corporation | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,364 | 21,602 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.79 per share. | 15 Mar 2022 | 3,304 | 765,761 (1%) | 0% | 15.8 | 52,170 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 175,649 | 993,659 (1%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Sale of securities on an exchange or to another person at price $ 34.55 per share. | 02 Feb 2022 | 70,447 | 923,212 (1%) | 0% | 34.5 | 2,433,725 | Common Stock |
| Glaukos Corporation | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,486 | 17,238 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO | Purchase of securities on an exchange or from another person at price $ 12.90 per share. | 29 Nov 2021 | 40,000 | 110,913 (0%) | 0% | 12.9 | 515,924 | Common Stock |
| Glaukos Corporation | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 2,382 | 14,752 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 73,665 | 73,665 | - | - | Employee Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 40,715 | 810,279 (1%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 1,184 | 12,370 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 301,000 | 714,500 (1%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.14 per share. | 30 Sep 2020 | 143,269 | 571,231 (1%) | 0% | 25.1 | 3,601,783 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 264,439 | 835,670 (1%) | 0% | - | Common Stock | |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.62 per share. | 23 Jul 2020 | 66,106 | 769,564 (1%) | 0% | 27.6 | 1,825,848 | Common Stock |
| Revance Therapeutics Inc | Mark J. Foley | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 50,913 | 70,913 (0%) | 0% | - | Common Stock | |
| SI-BONE Inc | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 8,797 | 8,797 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corporation | Mark J. Foley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 3,900 | 11,186 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges